First AD

Second AD

Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL

Video content above is prompted by the following:

How do you anticipate differentiating candidates for epcoritamab[JS1] + R

and those who might be better suited for a tafasitamab-lenalidomide-rituximab? What factors most influence your decision?

Feel free to share your thoughts on any differences and/or similarities in your impressions of the EPCORE NHL-2 trial, and potential treatment sequencing implications between tafasitamab-lenalidomide-rituximab vs epcoritamab + R

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights

Peer Exchange

Panelists discuss how they anticipate differentiating candidates for epcoritamab + lenalidomide and rituximab (R2) vs those better suited for tafasitamab-lenalidomide-rituximab, considering the factors that most influence their decisions, and share their impressions of the EPCORE NHL-2 trial, including potential treatment sequencing implications between the 2 regimens.